Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
2.
Lab Hematol ; 13(2): 56-8, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17573282

RESUMEN

A case of chronic lymphocytic leukemia is described in which peripheral blood films showed lymphocyte agglutination. A serum factor responsible for the agglutination was demonstrated. The factor was dependent upon the presence of anticoagulant solutions and was more active at room temperature than at 37 degrees C. It could be identified as a monoclonal immunoglobulin M. This mechanism has not been previously described in lymphocyte agglutination.


Asunto(s)
Aglutininas/sangre , Anticuerpos Monoclonales/sangre , Inmunoglobulina M/sangre , Cadenas lambda de Inmunoglobulina/sangre , Leucemia Linfocítica Crónica de Células B/sangre , Proteínas de Neoplasias/sangre , Anciano de 80 o más Años , Aglutinación/efectos de los fármacos , Pruebas de Aglutinación , Anticuerpos Monoclonales/farmacología , Anticoagulantes/farmacología , Subgrupos de Linfocitos B/inmunología , Subgrupos de Linfocitos B/patología , Ácido Edético/farmacología , Humanos , Leucocitos , Linfocitos , Masculino , Células Madre Neoplásicas/inmunología , Células Madre Neoplásicas/patología , Proteínas/análisis
3.
Leuk Res ; 30(8): 971-7, 2006 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-16423393

RESUMEN

The main objective of this study was to evaluate the role of the recent World Health Organization (WHO) classification for assessing prognosis in patients with myelodysplastic syndromes (MDS). To this effect, we analyzed the prognostic impact of the WHO and French-American-British (FAB) morphologic classifications and of four different scoring systems in a series of 311 patients with primary MDS diagnosed between October 1990 and June 2001. Both the FAB and WHO classifications identified groups with different prognoses (p<0.0001), those presenting refractory anemia (RA) and refractory anemia with ringed sideroblasts (RARS) showing the best prognosis. The WHO classification subdivided RA into RA with only red cell dysplasia, and refractory cytopenia with multilineage dysplasia (RCMD), and RARS into RARS plus refractory cytopenia with multilineage dysplasia and ringed sideroblast (RCMD-RS). In our population, we have shown that the two subtypes characterized by dysplasia affecting exclusively the erythroid population (RA and RARS) have a better prognosis, with a median survival of 122.2 and 81.9 months, respectively, than those with multilineage dysplasia (RCMD and RCMD-RS) with a median survival of 32.3 and 43.2 months, respectively. There were no significant differences in median survival comparing RA with RAS (p<0.95), or comparing RCMD with RSCMD (p<0.97). Besides, the four scoring systems discriminated our MDS patients in terms of survival, and an increase in prognostic capacity was achieved on adding the score to the morphological classifications. Risk scoring had a greater prognostic impact than the FAB and WHO classifications. Prognostic scoring systems may be an important tool for risk stratification in hematological practice, and add significance to morphological classification. Combined application of the WHO classification and score system is useful for improving the identification of patients with a poorer prognosis. The WHO classification establishes more homogeneous subcategories than the FAB classification and is also able to identify groups with different prognoses.


Asunto(s)
Síndromes Mielodisplásicos/clasificación , Síndromes Mielodisplásicos/diagnóstico , Índice de Severidad de la Enfermedad , Adulto , Anciano , Anciano de 80 o más Años , Anemia Refractaria/clasificación , Anemia Refractaria/diagnóstico , Anemia Sideroblástica/clasificación , Anemia Sideroblástica/diagnóstico , Análisis Citogenético , Femenino , Humanos , Cariotipificación , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Retrospectivos , Análisis de Supervivencia , Tasa de Supervivencia , Factores de Tiempo , Organización Mundial de la Salud
8.
Leukemia ; 11(8): 1383-5, 1997 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-9264398

RESUMEN

We describe the clinical and laboratory features of an unusual case with Sezary cell-like leukemia. Clinical manifestations were: anemia (Hb 9.4 g/dl), severe thrombocytopenia (5 x 10(9)/l), lymphocytosis (43 x 10(9)/l) and splenomegaly. There was no lymphadenopathy, hepatomegaly or skin lesions. Bone marrow trephine showed diffuse infiltration by atypical lymphoid cells. By ultrastructural analysis the cells were small to medium-size lymphocytes with nuclear features identical to Sezary cells. Immunophenotyping showed that most peripheral blood mononuclear cells were negative with B lymphoid, myeloid, and stem cell-associated markers and were also negative with most T lymphoid markers (CD2, CD4, membrane/cytoplasmic CD3, CD5 and CD8). However, they were positive with CD38 (70%), CD7 (25%) and TIA-2 (25%). Molecular analysis showed a clonal rearrangement of the TCR beta and gamma chain genes. The patient was initially treated with vincristine, doxorubicin and asparaginase and then with six cycles of CHOP, achieving a complete remission and remaining free of disease 22 months from diagnosis. Aberrant immunophenotypes are not frequent in primary T cell leukemias. This is the first case of a rare type of T cell neoplasm, Sezary cell-like leukemia, in which cells lacked most of the T cell-associated antigens.


Asunto(s)
Leucemia de Células T/patología , Adulto , Femenino , Humanos , Inmunofenotipificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...